Search clinical trials for: Sarilumab

Total 93 results

Dana-Farber Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN

Squamous Cell Carcinoma of the Head and Neck

United States
Tufts Medical Center

Not yet recruiting

Application of N-of-1 Rheumatoid Arthritis

Arthritis, Rheumatoid

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Leukemia | Chronic Lymphocytic Leukemia | Lymphocytic Leukemia

United States
Aetion, Inc.

Active, not recruiting

Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments

COVID-19

United States
Sanofi

Completed

Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (SARILNIUSATURN)

Uveitis

Italy, Turkey, Spain, United States, Czechia, France
Celldex Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Ovarian Carcinoma-Enrollment Completed | Colorectal Cancer (CRC)-Enrollment Completed | Renal Cell Carcinoma (RCC) (Phase ll Only) | Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed

United States
Sanofi
Regeneron Pharmaceuticals

Terminated

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate (RA-COMPARE)

Rheumatoid Arthritis

United States, Argentina, Australia, Brazil, Chile, Czechia, Finland, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Malaysia, Mexico, Peru, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, F... and more
PrECOG, LLC.
Bristol-Myers Squibb

Completed

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (PrE0807)

Bladder Cancer

United States
Innate Pharma

Completed

Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR) (EFFIKIR)

Acute Myeloid Leukemia

France
NYU Langone Health

Recruiting

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma | Unresectable Melanoma

United States
Bristol-Myers Squibb

Completed

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

CANCER, NOS

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Advanced Cancer

Japan
Nicholas Butowski
Celldex Therapeutics

Active, not recruiting

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Glioma | Malignant Glioma | Oligodendroglioma | Astrocytoma, Grade II | Glioma, Astrocytic | Oligoastrocytoma, Mixed

United States
Takeda

Completed

Single-Dose Study of MT203

Healthy Volunteers

Japan
Shinshu University

Recruiting

Usefulness of Non TNF Usage in RA Patients

Rheumatoid Arthritis

Japan
Incyte Corporation

Terminated

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

Solid Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Biphenotypic Leukemia

United States
Celldex Therapeutics

Terminated

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Neoplasms | Neoplasms by Histologic Type | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Clear-cell Metastatic Renal Cell Carcinoma

United States
Craig L Slingluff, Jr
Celldex Therapeutics

Completed

Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma (Mel-65)

Melanoma

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Leukemia

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
Annick Desjardins, MD
Celldex Therapeutics

Active, not recruiting

DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab (DERIVe)

Glioblastoma

United States
Bristol-Myers Squibb

Completed

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

CANCER,NOS

France, Canada, United States, Switzerland, Spain, Italy
Marie Hudson, MD
McGill University Health Centre/Research Institute of the McGill University... and other collaborators

Recruiting

Stand UP to Rheumatoid Arthritis (SUPRA) (SUPRA)

Rheumatoid Arthritis

Canada
Sanofi
Regeneron Pharmaceuticals

Completed

A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)

Rheumatoid Arthritis

Japan
Sanofi
Regeneron Pharmaceuticals

Terminated

Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

Rheumatoid Arthritis

United States, Italy, Mexico, Colombia, Czechia, Spain
Takeda

Terminated

Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate (TELLUS)

Rheumatoid Arthritis

Spain, Estonia, Russian Federation, Czechia, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Rheumatoid Arthritis

Hungary, Portugal, Austria, United States, Argentina, Australia, Brazil, Canada, Czechia, Germany, Greece, Guatemala, Israel, Italy, Korea, Republic of, Lithuania, Mexico, New Zealand, Peru, Poland, Romania, Russian Federation, Spain, Taiwa... and more
Medical University of Vienna
Medical University of Graz; Medical University Innsbruck; Hospital Hietzing; Krankenhaus...

Not yet recruiting

Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis

Rheumatoid Arthritis
Celldex Therapeutics

Terminated

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Melanoma

United States
Takeda

Completed

Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) (NEXUS)

Rheumatoid Arthritis

Poland, Spain, Bulgaria, Russian Federation, Czechia, Japan, Korea, Republic of, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis (SariPRO)

Rheumatoid Arthritis

France
Sanofi
Regeneron Pharmaceuticals

Completed

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

Rheumatoid Arthritis

United States, Argentina, Belgium, Brazil, Czechia, Estonia, Finland, Hungary, Israel, Italy, Mexico, Netherlands, Poland, Romania, Russian Federation, Spain, Sweden, United Kingdom, Norway
Sanofi
Regeneron Pharmaceuticals

Completed

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis (SARIL-RA-EASY)

RA

United States, Chile, Mexico, Poland, Russian Federation, South Africa
Bristol-Myers Squibb
Janssen, LP

Active, not recruiting

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Multiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin's Lymphoma

United States, Poland, Italy, Belgium, France, Greece
John Harris

Recruiting

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Allergic Contact Dermatitis | Skin Inflammation

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Plasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditions

United States
University of Nebraska

Recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Rheumatoid Arthritis

United States
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Recruiting

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors (ESMART)

Pediatric Cancer

Italy, France, Denmark, Germany, Netherlands, Spain, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Recurrent Gallbladder Carcinoma | Metastatic Gallbladder Carcinoma | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Recurrent Intrahepatic Cholangiocarcinoma | Metastatic... and other conditions

United States
UMC Utrecht
National University Hospital, Singapore; Berry Consultants; University of Pittsburgh... and other collaborators

Recruiting

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP)

Community-acquired Pneumonia, Influenza, COVID-19

United Kingdom, United States, Canada, Australia, Netherlands, Croatia, Germany, Belgium, New Zealand, Ireland, Spain, Japan, Hungary, Colombia, India, Nepal, Pakistan, Portugal, Romania, Saudi Arabia
Duke University
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)

Heart Failure | Pain | Pneumonia | Hypertension | Edema | Hemophilia | Insomnia | Pulmonary Arterial Hypertension | Coagulation Disorder | Asthma in Children | Down Syndrome | Attention Deficit Hyperactivity Disorder | Bronchopulmonary Dysplasia | Hypokalemia | Hyperphosphatemia | Primary Hyperaldosteronism | Adrenal Insufficiency and other conditions

United States, Canada

Search clinical trials for: Sarilumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations